Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNTOCINON vs OXYTOCIN 5 USP UNITS IN DEXTROSE 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, increasing intracellular calcium and stimulating uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to promote milk ejection.
Induction or augmentation of labor,Facilitation of abortion in the second trimester,Postpartum hemorrhage prevention and treatment
Induction or augmentation of labor,Facilitation of milk ejection,Treatment of postpartum hemorrhage (off-label)
10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.
Induction or augmentation of labor: IV infusion, initial rate 0.5-2 m U/min, increased by 1-2 m U/min every 15-30 min until adequate contractions; max 20 m U/min. Postpartum hemorrhage: IV infusion 10-40 units in 1000 m L D5W or NS, rate adjusted to control bleeding.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Terminal elimination half-life: 1–6 minutes (intravenous); 2–5 minutes (intramuscular); short half-life requires continuous infusion for sustained effect.
Rapidly metabolized in the liver and kidneys by oxytocinase (cysteine aminopeptidase) and other peptidases.
Rapidly metabolized in the liver and kidneys by oxytocinase (cystinyl aminopeptidase) and other peptidases. Small amounts are excreted unchanged in urine.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Renal (primarily); >99% of infused oxytocin is excreted unchanged in urine; negligible biliary/fecal elimination.
Low (~30%); primarily binds to albumin and oxytocin-specific carrier proteins (e.g., neurophysin I).
Low; approximately 30% bound to plasma proteins (no specific carrier protein identified).
0.2–0.3 L/kg; reflects limited distribution into extracellular fluid and minimal tissue binding.
0.2–0.3 L/kg; small Vd consistent with distribution primarily in extracellular fluid; does not readily cross placenta.
Intramuscular: ~20–40% (due to rapid enzymatic degradation); Intravenous: 100%.
Intravenous: 100%; Intramuscular: approximately 50% (due to first-pass hepatic metabolism after absorption).
No dosage adjustment required for renal impairment; oxytocin is rapidly metabolized and renally excreted, but no specific GFR-based guidelines exist.
No dosage adjustment required for renal impairment. Oxytocin is extensively metabolized and renal excretion of unchanged drug is minimal.
No dosage adjustment required for hepatic impairment; oxytocin is metabolized primarily by the liver, but no Child-Pugh based modifications have been established.
No dosage adjustment required for hepatic impairment. Oxytocin metabolism by liver is not significantly altered in liver disease.
Not indicated for pediatric use; safety and efficacy in children have not been established.
Not indicated for pediatric use. Oxytocin is only used in obstetrics for labor induction or postpartum hemorrhage in adults.
Use with caution in elderly patients due to potential for uterine hyperstimulation and adverse cardiovascular effects; no specific dosage adjustments recommended.
Not indicated for geriatric use. Oxytocin is exclusively used in women of childbearing age for obstetrical indications.
NOT FOR ELECTIVE INDUCTION OF LABOR AT TERM DUE TO RISK OF UTERINE HYPERSTIMULATION, UTERINE RUPTURE, AND FETAL DISTRESS. SHOULD ONLY BE USED UNDER CONTINUOUS MEDICAL SUPERVISION WITH FETAL AND UTERINE MONITORING.
WARNING: UTERINE RUPTURE AND FETAL INJURY. To be used only under close medical supervision. High doses or prolonged use may lead to uterine hyperstimulation, tetanic contractions, and uterine rupture. Fetal heart rate must be monitored continuously.
Uterine hyperstimulation and tetany,Uterine rupture, especially in grand multipara or with prior cesarean,Water intoxication and hyponatremia due to antidiuretic effect (high doses),Fetal bradycardia, hypoxia, and neonatal jaundice,Hypotension and tachycardia with rapid IV administration
Risk of uterine hyperstimulation, fetal distress, uterine rupture, water intoxication (especially when administered with large volumes of electrolyte-free solutions), severe hypotension, and anaphylaxis. Monitor uterine activity, fetal heart rate, and fluid balance.
Hypersensitivity to oxytocin or any component,Cephalopelvic disproportion,Fetal distress where delivery is not imminent,Prolapsed umbilical cord,Placenta previa,Vasa previa,Contraindicated for elective induction in term pregnancies
Significant cephalopelvic disproportion, unfavorable fetal position, fetal distress, preterm labor (unless tocolysis is desired), uterine scarring (e.g., previous Cesarean section), invasive cervical carcinoma, hypertonic uterine patterns, allergy to oxytocin, and cases where vaginal delivery is contraindicated.
No food interactions are known. However, because oxytocin can cause water retention, advise moderate sodium intake to reduce risk of hyponatremia. No specific dietary restrictions.
None known. Patient should avoid excessive fluid intake to prevent water intoxication due to oxytocin's antidiuretic effect.
Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bradycardia, and neonatal hyperbilirubinemia. No trimester-specific malformation risk is established; uterine hyperstimulation risk is greatest during second and third trimester use.
FDA Pregnancy Category C. Oxytocin is not expected to increase the risk of major birth defects when used as indicated for labor induction/augmentation. However, high doses may cause uterine hyperstimulation leading to fetal distress, hypoxia, or neonatal morbidity. First trimester exposure is minimal as use is typically restricted to labor. No teratogenicity observed in animal studies but fetal risks are primarily related to uterotonic effects.
Oxytocin is endogenous in breast milk; exogenous administration does not significantly increase milk levels. M/P ratio not clinically relevant due to rapid metabolism. Considered compatible with breastfeeding.
Limited data; M/P ratio not established. Oxytocin is rapidly metabolized and excreted in breast milk in negligible amounts. Endogenous oxytocin is normally present in milk. Exogenous use during lactation is unlikely to affect the infant due to rapid plasma clearance (half-life 3-5 minutes). Caution advised if used postpartum for hemorrhage.
No standard dose adjustment required due to pregnancy-induced pharmacokinetic changes. However, uterine sensitivity to oxytocin increases with gestational age; lower starting doses may be used near term to avoid hyperstimulation.
Pregnancy does not require dose adjustment per se, but dose must be titrated carefully based on uterine response and fetal status. Pharmacokinetic changes (increased plasma volume, enhanced clearance by placental oxytocinase) may necessitate higher infusion rates to achieve desired effect. Start at low dose (0.5-2 m U/min) and increase by 1-2 m U/min at 30-60 minute intervals. Maximum dose typically 20 m U/min; higher doses increase adverse effects.
Syntocinon (oxytocin) is used for induction or augmentation of labor. Administer via controlled IV infusion using an infusion pump. Start at 0.5-2 m U/min and titrate every 30-60 min to achieve adequate contractions (3-5 per 10 min). Monitor for uterine hyperstimulation, fetal distress, or water intoxication (antidiuretic effect). Have magnesium sulfate, terbutaline, or other tocolytics available for hyperstimulation. Do not use if contraindicated (e.g., cephalopelvic disproportion, fetal distress, placenta previa).
Oxytocin should be administered as a controlled intravenous infusion via infusion pump to avoid uterine hyperstimulation. Initiate at 0.5-2 m U/min and titrate by 1-2 m U/min every 30-60 minutes as needed. Monitor fetal heart rate, uterine activity (tone, frequency, duration), and maternal vital signs continuously. Have magnesium sulfate available for tocolysis if hyperstimulation occurs. Oxytocin has antidiuretic effect; monitor fluid balance to avoid water intoxication. Nasal formulation not for induction/augmentation.
Syntocinon is given intravenously to start or strengthen labor contractions.,You will be closely monitored with an electronic fetal monitor.,Report any excessively frequent or prolonged contractions or severe pain immediately.,It may increase the risk of postpartum hemorrhage; staff is prepared to manage it.,Tell your healthcare provider about any history of heart disease or high blood pressure.
Report any uterine contractions that are too frequent or painful, or changes in fetal movement.,You will be continuously monitored for your and your baby's heart rates and uterine activity.,Inform your healthcare provider if you experience headache, nausea, vomiting, or confusion (signs of fluid overload).,Do not adjust the infusion rate yourself; it will be controlled by the medical team.,This medication is used to start or strengthen labor contractions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNTOCINON vs OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, answered by our medical review team.
SYNTOCINON is a Oxytocic that works by Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.. OXYTOCIN 5 USP UNITS IN DEXTROSE 5% is a Oxytocic that works by Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, increasing intracellular calcium and stimulating uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to promote milk ejection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNTOCINON and OXYTOCIN 5 USP UNITS IN DEXTROSE 5% depend on the specific clinical indication. These are both Oxytocic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNTOCINON is: 10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.. The standard adult dose of OXYTOCIN 5 USP UNITS IN DEXTROSE 5% is: Induction or augmentation of labor: IV infusion, initial rate 0.5-2 m U/min, increased by 1-2 m U/min every 15-30 min until adequate contractions; max 20 m U/min. Postpartum hemorrhage: IV infusion 10-40 units in 1000 m L D5W or NS, rate adjusted to control bleeding.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNTOCINON and OXYTOCIN 5 USP UNITS IN DEXTROSE 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNTOCINON is classified as Category C. Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bra. OXYTOCIN 5 USP UNITS IN DEXTROSE 5% is classified as Category C. FDA Pregnancy Category C. Oxytocin is not expected to increase the risk of major birth defects when used as indicated for labor induction/augmentation. However, high doses may caus. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.